HCN Tissue Bank: Tissue/Body Fluid Procurement and Clinical Data Collection for Patients with Malignancies of the Head and Neck Area and/or Pre-Malignant Changes
Aims: The purpose of this study is to collect tissue, blood, saliva, and/or clinical data (information about your treatment) from patients with a cancer in the head and neck area (or pre-malignant lesions) for research purposes. Certain genetic and biochemical changes are believed to lead to the development of head and neck cancer. Scientists are attempting to discover and understand the function of these changes. In the future, an improved understanding of these changes may help us to better detect head and neck cancers and offer improved treatments.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH13-276
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
RTOG-1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Aims: The purpose of this part of this study is to find out what effects, good and/or bad, one of the following treatments has on you and your cancer. In this part of the study, you will receive one of the following treatments:
- Standard treatment: radiation therapy and cisplatin
- Experimental treatment: radiation therapy and docetaxel
- Experimental treatment: radiation therapy, docetaxel, and cetuximab
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH15-004
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment- yes
NRG-HN005: A Randomized Phase II/III Trial of De-intensifed Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Aims: The purpose is to compare if a reduced dose of radiation along with chemotherapy or immunotherapy results in the same length of time without your cancer getting worse as the usual approach.
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH20-014
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
EA3163: Phase II Randomized Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Post-operative Radiation Versus Surgery and Post-operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma
Aims: The purpose is to compare 2 treatment approaches to see which would improve the preservation of the eye or skull bone and increase overall survival.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH19-287
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
Merck 3475-689: A Phase III Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Aims: The purpose of this study is to compare any good and bad effects of adding pembrolizumab to radiation and chemotherapy before and after surgery.
Diagnosis: Head and Neck Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH18-073
Sponsor: Merck
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
Regeneron: Cemiplimab Survivorship Epidemiology (Case) Study
Aims: The purpose of this study is to determine the long-term effectiveness and safety of cemiplimab-rwlc in patients.
Diagnosis: Head and Neck Cancer
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH19-250
Sponsor: Regeneron Pharmaceuticals
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
MNPR-301-001: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Patients with Oropharyngeal Cancer.
Aims: The purpose of this study is to determine the efficacy and safety of Clonidine mucoadhesive tablet in preventing oral mucositis in patients getting chemotherapy and radiation therapy.
Diagnosis: Head and Neck Cancer
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH22-047
Sponsor: Monopar
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes